Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review by Alice Caldiroli, Enrico Capuzzi, Ilaria Tagliabue, Martina Capellazzi, Matteo Marcatili, Francesco Mucci, Fabrizia Colmegna, Massimo Clerici, Massimiliano Buoli, Antonios Dakanalis

“…The efficacy of adjunctive ADs, antiepileptic drugs, psychostimulants, pramipexole, ropinirole, acetyl-salicylic acid, metyrapone, reserpine, testosterone, T3/T4, naltrexone, SAMe, and zinc cannot be precisely estimated in light of the limited available data. …”
Get full text

The effects of long-term dopaminergic treatment on locomotor behavior in rats by Welinton Alessandro Oliveira de Almeida, Andrea Maculano Esteves, Canuto Leite de Almeida-Júnior, Kil Sun Lee, Miriam Kannebley Frank, Melise Oliveira Mariano, Roberto Frussa-Filho, Sergio Tufik, Marco Tulio de Mello

“…The rats were divided into control (CTRL) and drug (Pramipexole—PPX) groups that received daily saline vehicle and PPX treatments, respectively, for 71 days. …”
Get full text

Parkinson’s disease in a patient with GBA and LRRK2 covariants after acute hypoxic insult: a case report by Yuting Tang, Lijian Wei, Zhuohua Wu, Pingyi Xu, Mingshu Mo

“…These symptoms were treated with levodopa and pramipexole, resulting in a 65% improvement in the Unified Parkinson’s Disease Rating Scale (UPDRS) motor score. …”
Get full text

Effectiveness of Integrative Therapy for Parkinson’s Disease Management by Yeonju Woo, Min Kyung Hyun

“…Sex, age, index year, comorbidity, severity of disability, neurologic care, and anti-parkinsonism medication (levodopa, ropinirole, pramipexole, selegiline) were adjusted in both groups. …”
Get full text

Concurrent diagnoses of treatment-induced neuropathy of diabetes and restless leg syndrome by Sarah Kanbour, Aanika Balaji, Nicholas Maragakis, Nicholas Stanley Clarke, Nestoras Mathioudakis

“…He was later found to have anemia and diagnosed with concurrent RLS, for which he was treated with carbidopa-levodopa and later pramipexole. Over the course of 18 months, his neuropathic symptoms resolved completely. …”
Get full text

A rare case of sleep - related rhythmic movement disorder in adult with literature review by Yue HOU, Zhao-yang HUANG, Yu-ping WANG, Shu-qin ZHAN

“…The diagnosis was RMD, clonazepam 0.50 mg/night and pramipexole 0.0625 mg/night were given and the result of 33 months follow-up showed effective. …”
Get full text

Quantification of Non-Motor Symptoms in Parkinsonian Cynomolgus Monkeys by Yu Bao, Chaoning Gan, Zuyue Chen, Zhongquan Qi, Zhiqiang Meng, Feng Yue

“…In addition, we tested whether the dopamine receptor agonist pramipexole (PPX) can improve these non-motor symptoms. …”
Get full text

Treatment-Resistant Bipolar Depression: Therapeutic Trends, Challenges and Future Directions by Elsayed OH, Ercis M, Pahwa M, Singh B

“…In this paper, we review the evidence base of therapeutic interventions, challenges, and potential future directions for TRBD.Methods: We conducted a literature search for randomized controlled trials on PubMed for the treatment of TRBD and ongoing trials for the treatment of TRBD/bipolar depression on clinicaltrials.gov.Results: Several therapeutic agents have been investigated for TRBD. Adjunctive pramipexole and modafinil have data supporting short-term efficacy in TRBD, along with limited data for racemic intravenous ketamine. …”
Get full text

Efficacy and safety of adjunctive oral therapy in Parkinson’s disease with motor complications: a systematic review and network meta-analysis by Joao Costa, Joke M Dijk, Rob M A de Bie, Gonçalo S Duarte, Vibuthi Sisodia, Lars Dubbeld

“…According to surface under the cumulative ranking curve scores, pramipexole IR was associated with the most favourable benefit–risk profile.Conclusions COMT-Is, DRAs and MAOB-Is effectively reduce motor complications and increase incidence of dyskinesia. …”
Get full text

Neuroprotective Effects of Ellagic Acid in a Rat Model of Parkinson's Disease by Alireza Sarkaki, Yaghoob Farbood, Mojtaba Dolatshahi, Seyed Mohammad Taqhi Mansouri, Ali Khodadadi

“…One group of MFB-lesioned rats received pramipexole (PPX; 2 mg/kg/2 ml, by gavages) as a positive control group (PD+PPX group). …”
Get full text

The Effect of Wet Cupping Therapy on Patients' Symptom Level and Sleep Quality on Restless Leg Syndrome by Gülsüm Yurttutan, Basri Furkan Dağcıoğlu

“…The first group consisted of patients who currently received pramipexole therapy, and the second group consisted of patients who received no medical treatment. …”
Get full text

Antinociceptive effect of LMH-2, a new sigma-1 receptor antagonist analog of haloperidol, on the neuropathic pain of diabetic mice by Rosa Ventura-Martínez, Guadalupe Esther Ángeles-López, Diana González-Ugalde, Tania Domínguez-Páez, Gabriel Navarrete-Vázquez, Ruth Jaimez, Myrna Déciga-Campos

“…Moreover, the antiallodynic and antihyperalgesic effect of both LMH-2 and HAL were completely abolished by PRE-084 (σ1 R agonist); and partially by pramipexole (a D2-like receptor agonist). Finally, the effect of all treatments on the rotarod test, barra, open field and exploratory behaviors showed that LMH-2 did not alter the animals' balance or the exploratory behavior, unlike as HAL or GBP. …”
Get full text

Fluoxetine versus other types of pharmacotherapy for depression by Cipriani, A, Brambilla, P, Furukawa, T, Geddes, J, Gregis, M, Hotopf, M, Malvini, L, Barbui, C

“…Fluoxetine was better tolerated than TCAs considered as a group (Peto OR: 0.78, 95% CI 0.68 to 0.89), and was better tolerated in comparison with individual ADs, in particular than amitriptyline (Peto OR: 0.64, 95% CI 0.47 to 0.85) and imipramine (Peto OR: 0.79, 95% CI 0.63 to 0.99), and among newer ADs than ABT-200 (Peto OR: 0.21, 95% CI 0.10 to 0.41), pramipexole (Peto OR: 0.20, 95% CI 0.08 to 0.47) and reboxetine (Peto OR: 0.61, 95% CI 0.40 to 0.94). …”

Fluoxetine versus other types of pharmacotherapy for depression. by Cipriani, A, Brambilla, P, Furukawa, T, Geddes, J, Gregis, M, Hotopf, M, Malvini, L, Barbui, C

“…Fluoxetine was better tolerated than TCAs considered as a group (PetoOR: 0.78, 95% CI 0.68 to 0.89), and was better tolerated in comparison with individual ADs, in particular than amitriptyline (PetoOR: 0.64, 95% CI 0.47 to 0.85) and imipramine (PetoOR: 0.79, 95% CI 0.63 to 0.99), and among newer ADs than ABT-200 (PetoOR: 0.21, 95% CI 0.10 to 0.41), pramipexole (PetoOR: 0.20, 95% CI 0.08 to 0.47) and reboxetine (PetoOR: 0.61, 95% CI 0.40 to 0.94). …”